---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-254698"
form_type: "8-K"
ticker: "KYTX"
cik: "0001994702"
company_name: "Kyverna Therapeutics, Inc."
filed_at: "2025-10-29T23:59:59+00:00"
generated_at: "2026-05-17T01:44:52.448865+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "low"
source: SEC EDGAR
---

# Kyverna reports positive interim Phase 2 data for KYV-101 in generalized myasthenia gravis

## Summary
- Positive interim data from Phase 2 portion of KYSA-6 trial of KYV-101 announced on October 29, 2025.
- Conference call held same day at 8 a.m. Eastern Time to discuss results; slides furnished as Exhibit 99.1.
- No specific efficacy or safety figures included in the filing text; detailed data in attached slide deck.
- Kyverna is a clinical-stage biotech focused on CAR T-cell therapies for autoimmune diseases.

## SEC filing metadata
- accession: 0001193125-25-254698
- form_type: 8-K
- ticker: KYTX
- cik: 0001994702
- company_name: Kyverna Therapeutics, Inc.
- filed_at: 2025-10-29T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: low
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1994702/000119312525254698/0001193125-25-254698-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1994702/000119312525254698/d59631d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-254698
- JSON: https://secwatch.observer/filing/0001193125-25-254698.json
- Plain text: https://secwatch.observer/filing/0001193125-25-254698.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.